Lilly to bag Loxo Oncology for $8 billion8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.
Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.
The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing. For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.
Loxo Oncology has a promising portfolio of approved and investigational medicines, including
"Using tailored medicines to target key tumour dependencies offers an increasingly robust approach to cancer treatment," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories. "Loxo Oncology's portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer."
"We are gratified that Lilly has recognized our contributions to the field of precision medicine and are excited to see our pipeline benefit from the resources and global reach of the Lilly organization," said Josh Bilenker, CEO of Loxo Oncology. "Tumour genomic profiling is becoming standard-of-care, and it will be critical to continue innovating against new targets, while anticipating mechanisms of resistance to available therapies, so that patients with advanced cancer have the chance to live longer and better lives."
"Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives," said Anne White, president of Lilly Oncology. "The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology."
"We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need," said Jacob Van Naarden, chief operating officer of Loxo Oncology. "We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase II to discovery, will continue to thrive in Lilly's hands."
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Catalent invests over $27 million to commercialize Zydis Ultra
7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation